Featured Research

from universities, journals, and other organizations

FDA Approves First-of-Kind Device To Treat Descending Thoracic Aneurysms

Date:
April 20, 2005
Source:
U.S. Food And Drug Administration
Summary:
The Food and Drug Administration (FDA) has approved a new device that is intended to prevent ruptures of descending thoracic aneurysms by making a new path for blood flow. The GORE TAG Endoprosthesis System is the first endovascular grafting system approved to treat aneurysms of the thoracic aorta, the main artery that carries blood in the body.

March 23, 2005 -- The Food and Drug Administration (FDA) today approved a new device that is intended to prevent ruptures of descending thoracic aneurysms by making a new path for blood flow. The GORE TAG Endoprosthesis System is the first endovascular grafting system approved to treat aneurysms of the thoracic aorta, the main artery that carries blood in the body.

A thoracic aortic aneurysm is a diseased, weakened, and bulging section of the aorta in the chest. This condition, if not treated, could result in a rupture (bursting) of the aorta, leading to life-threatening internal bleeding. The aneurysm may be caused by vascular disease, injury, or an inherited (genetic) defect of the tissue.

The GORE TAG Endoprosthesis System consists of an endovascular graft made of ePTFE (expanded polytetrafluoroethylene) and a metallic support structure, and a delivery system used to implant the graft. The endovascular graft is delivered by a catheter inserted into the femoral artery in the groin. The graft re-lines the inside of the weakened aortic wall, thus strengthening the vessel and relieving pressure that could cause a rupture. The procedure, while less-invasive, than conventional surgery, does require regular follow-up medical visits and tests to monitor the success of the treatment over time.

Typically, descending thoracic aneurysms are managed either medically with blood pressure-lowering drugs to reduce risk of rupture, or by surgical repair. Large aneurysms are at significant risk of rupture, which often is fatal. Conventional surgical repair requires a major chest operation in which the aneurysm is replaced by a graft. Such surgery is associated with prolonged hospitalization, post-operative monitoring in an intensive care unit, and a recuperation period of three to six months.

FDA approved the Endoprosthesis System based on review of two clinical studies of the System’s safety and effectiveness. These studies involved approximately 200 people. Study results showed that aneurysm-related deaths were lower in patients who had received the endoprosthesis than in the surgical control group.

FDA is requiring that Gore conduct post-approval studies to assure that when the endovascular grafting system is used in the large general population, its safety and effectiveness will be comparable to the clinical trials, and to evaluate the long-term clinical performance of the device.

The GORE TAG Endoprosthesis System is manufactured by W.L. Gore and Associates, Inc. of Flagstaff, Arizona.


Story Source:

The above story is based on materials provided by U.S. Food And Drug Administration. Note: Materials may be edited for content and length.


Cite This Page:

U.S. Food And Drug Administration. "FDA Approves First-of-Kind Device To Treat Descending Thoracic Aneurysms." ScienceDaily. ScienceDaily, 20 April 2005. <www.sciencedaily.com/releases/2005/04/050419112017.htm>.
U.S. Food And Drug Administration. (2005, April 20). FDA Approves First-of-Kind Device To Treat Descending Thoracic Aneurysms. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2005/04/050419112017.htm
U.S. Food And Drug Administration. "FDA Approves First-of-Kind Device To Treat Descending Thoracic Aneurysms." ScienceDaily. www.sciencedaily.com/releases/2005/04/050419112017.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins